<乌鸦传媒>Raise a Glass? Study Tallies Cancer Cases From Booze Heavy drinking habits accounted for about half of new alcohol-associated cases Jul 13, 2021
<乌鸦传媒>Could Docetaxel Have Role in Unfavorable-Risk Prostate Cancer? Use of chemo reduced radiation-induced cancers, and may prolong OS in low-PSA subgroup Jul 07, 2021
<乌鸦传媒>Infusion Centers or EDs for Sickle Cell Crises? Adults with SCD treated in infusion centers had improved outcomes in three key measures Jul 06, 2021
<乌鸦传媒>IVF Babies at No Increased Risk of Childhood Cancers No associations seen with intracytoplasmic sperm injection or frozen embryo transfer, study found Jul 02, 2021
<乌鸦传媒>Hold Off on Approving Anal Cancer Drug, Advisors Tell FDA ODAC recommends deferring approval of new PD-1 inhibitor until confirmatory trial results are in Jun 24, 2021
<乌鸦传媒>No Survival Benefit With All-Oral Regimen for Relapsed/Refractory Myeloma Prolonging PFS a positive, as advances make OS improvement harder to achieve Jun 18, 2021
<乌鸦传媒>Start Thinking 'Cure'; One More Hug; Mortgages and Breast Cancer Survival News, features, and commentary about cancer-related issues Jun 16, 2021
<乌鸦传媒>Fixed-Duration, All-Oral Regimen Slows CLL Progression Near-80% reduction in PFS hazard with ibrutinib-venetoclax versus obinutuzumab-chlorambucil Jun 16, 2021
<乌鸦传媒>How CAR T-Cell Therapy Measures Up in Follicular Lymphoma Better response rates and survival with axicabtagene ciloleucel versus external control group Jun 15, 2021
<乌鸦传媒>Zanubrutinib Tops Ibrutinib in Relapsed or Refractory CLL Better overall response rate, less cardiotoxicity, with second-generation BTK inhibitor Jun 14, 2021
<乌鸦传媒>COVID Vaccine Protection; 'Until You Die From the Cancer'; What's Palliative Care? News, features, and commentary about cancer-related issues Jun 10, 2021
<乌鸦传媒>Another CAR-T Impresses in Follicular Lymphoma Complete responses in 66% of patients with relapsed or refractory disease Jun 08, 2021
<乌鸦传媒>Combination Therapy Achieves High Response in Ph+ ALL Ponatinib-blinatumomab offers promising regimen in frontline and relapse/refractory disease Jun 05, 2021
<乌鸦传媒>With Supplements, ADT in Prostate Cancer of Little Threat to Bone Density Study suggests calcium/vitamin D alone sufficient for long-duration therapy Jun 03, 2021
<乌鸦传媒>Family Alleges Profit Motives Played Role in 3-Year-Old's Death Parents charge care delays for child with hydrocephalus were tied to arrangements for star doctor May 25, 2021
<乌鸦传媒>Thiotepa-Based Conditioning Promising for Primary CNS Lymphoma Commonly used regimens with autologous transplant improved survival May 06, 2021
<乌鸦传媒>Vadadustat Matches Standard for CKD-Related Anemia, With Caveat Jury still out on drug's heart safety, which differed depending on dialysis dependence Apr 28, 2021
<乌鸦传媒>Healthy Lifestyle May Mitigate Heart Risks for Young Cancer Survivors Literature reviews find particularly persistent cardiovascular complications in these patients Apr 28, 2021
<乌鸦传媒>Why Clotting Happens When Platelets Are Low A hematologist explains the counterintuitive concept of clots with low platelets Apr 23, 2021
<乌鸦传媒>Poloxamer 188 Flops for Sickle Cell Disease Pain Study found no difference in duration of vaso-occlusive episodes versus placebo Apr 20, 2021
<乌鸦传媒>Targeted Drug Yields Durable Responses in Rare Blood Neoplasm Most advanced systemic mastocytosis patients responded to KIT D816V inhibitor Apr 13, 2021
<乌鸦传媒>Add-On PI3K Inhibitor Wins in Relapsed, Indolent NHL Adding copanlisib to rituximab also doubled CR rate, with manageable toxicity Apr 10, 2021
<乌鸦传媒>From VIPIT to VITT: Thrombosis and COVID Vaccines More data support link between adenovirus vector vaccines, blood clotting, and low platelets Apr 09, 2021
<乌鸦传媒>Ethics Consult: Stop Treatment for Costly Patient? MD/JD Weighs In You voted, now see the results and an expert's discussion Apr 09, 2021
<乌鸦传媒>Vaccines and Rare Clotting Disorders: What's the Link? Causal relation appears possible, but evidence still indicates it's extremely rare Mar 25, 2021
<乌鸦传媒>Marrow Cell Stimulator to Treat Alzheimer's Disease? Unusual approach pans out in mid-stage trial Mar 24, 2021
<乌鸦传媒>Op-Ed: Blood Cancer Patients Need More COVID Vax Answers Patients are left wondering, "will I be protected?" Mar 24, 2021
<乌鸦传媒>C3 Inhibitor Prevails in Trial of Rare Hemoglobinuria Improvement in hemoglobin, transfusion independence with pegcetacoplan for PNH Mar 17, 2021
<乌鸦传媒>Holding tPA for All DOAC Users Not the Way to Go, Stroke Docs Say Clinical conundrum could be solved by a point-of-care DOAC test Mar 15, 2021
<乌鸦传媒>Study Confirms Risk-Adapted CRS Prophylaxis for Acute Leukemia Tocilizumab reduced severe cytokine release syndrome in children, young adults Mar 09, 2021
<乌鸦传媒>Anti-CD20 Drugs Tied to Severe COVID in Cancer Patients Plus: Active chemo treatment may not be a COVID risk factor Feb 05, 2021
<乌鸦传媒>Preventive Approach to C-Section Bleeding Pans Out in Trial Treatment lowered risk of early blood loss and transfusion, but not more severe hemorrhage Jan 29, 2021
<乌鸦传媒>Officials Investigate Physician's Death After COVID Vaccination Onset of rare blood disorder should not be interpreted as causal, experts say Jan 27, 2021
<乌鸦传媒>JAK Inhibitor Misses Endpoint in Safety Study. Now What? Major blow to popular class of oral rheumatology drugs Jan 27, 2021
<乌鸦传媒>Ethics Consult: Refuse Treatment for Dictator? MD/JD Weighs In You voted, now see the results and an expert's discussion Jan 15, 2021
<乌鸦传媒>PARP Inhibitors Linked With Blood Cancer Risk Incidence of MDS/AML under 1%, but further investigation warranted as indications broaden Dec 28, 2020
<乌鸦传媒>Non-Hodgkin Lymphoma: Bispecific Antibodies Impress in Refractory Disease Odronextamab, epcoritamab surpass 90% response threshold in early trials Dec 11, 2020
<乌鸦传媒>Chemo-Free Combo Boosts PFS in First-Line CLL PI3K-delta-based regimen also topped chemoimmunotherapy in relapsed setting Dec 08, 2020
<乌鸦传媒>Novel Agent Active in Refractory CML Asciminib doubles molecular response versus bosutinib after two or more prior lines of therapy Dec 08, 2020
